{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:06:37Z","timestamp":1779350797527,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11739-017-1708-7","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:55:16Z","timestamp":1499648116000},"page":"1043-1053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-2897","authenticated-orcid":false,"given":"Alessandro","family":"Squizzato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Basilio","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Nerone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Patrick","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Maria","family":"Maresca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Campiotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"1708_CR1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L et al (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neural differentiation. Proc Natl Acad Sci USA 100:928\u2013933","journal-title":"Proc Natl Acad Sci USA"},{"key":"1708_CR2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e9s JP et al (2003) Mutation in PSCK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154\u2013156","journal-title":"Nat Genet"},{"key":"1708_CR3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11883-010-0123-6","volume":"12","author":"J Davignon","year":"2010","unstructured":"Davignon J, Dubuc G, Seidah NG (2010) The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 12:308\u2013315","journal-title":"Curr Atheroscler Rep"},{"key":"1708_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"JC Cohen","year":"2005","unstructured":"Cohen JC, Pertsemlidis A, Kotowski IK et al (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161\u2013165","journal-title":"Nat Genet"},{"key":"1708_CR5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr et al (2006) Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med 354:1264\u20131272","journal-title":"N Engl J Med"},{"key":"1708_CR6","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","volume":"55","author":"M Benn","year":"2010","unstructured":"Benn M, Nordestgaard BG, Grande P et al (2010) PCSK9 R46L, low density lipoprotein cholesterol levels and risk of ischemic heart disease: 3 independent studies and meta analyses. J Am Coll Cardiol 55:2833\u20132842","journal-title":"J Am Coll Cardiol"},{"key":"1708_CR7","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","volume":"102","author":"S Rashid","year":"2005","unstructured":"Rashid S, Curtis DE, Garuti R et al (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Nat Acad Sci USA 102:5374\u20135379","journal-title":"Proc Nat Acad Sci USA"},{"issue":"264\u2013269","key":"1708_CR8","doi-asserted-by":"crossref","first-page":"W264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264\u2013269):W264","journal-title":"Ann Intern Med"},{"key":"1708_CR9","first-page":"d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. 343:d5928","journal-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials."},{"key":"1708_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"1708_CR11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"1708_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, Gaudet D et al (2012) Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380:29\u201336","journal-title":"Lancet"},{"key":"1708_CR13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","volume":"78","author":"A Hirayama","year":"2014","unstructured":"Hirayama A, Honarpour N, Yoshida M et al (2014) Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2014primary results from the phase 2 YUKAWA Study. Circ J 78:1073\u20131082","journal-title":"Circ J"},{"key":"1708_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ et al (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385:341\u2013350","journal-title":"Lancet"},{"key":"1708_CR15","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R et al (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C With PCSK9 Inhibition in heterozygous familial Hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126:2408\u20132417","journal-title":"Circulation"},{"key":"1708_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R et al (2015) PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:331\u2013340","journal-title":"Lancet"},{"key":"1708_CR17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ et al (2014) Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 129:234\u2013243","journal-title":"Circulation"},{"key":"1708_CR18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Eng J Med. 372:1500\u20131509","journal-title":"N Eng J Med."},{"key":"1708_CR19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","volume":"244","author":"M Farnier","year":"2016","unstructured":"Farnier M, Jones P, Severance R et al (2016) Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244:138\u2013146","journal-title":"Atherosclerosis"},{"key":"1708_CR20","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R et al (2015) Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 100:3140\u20133148","journal-title":"J Clin Endocrinol Metab"},{"key":"1708_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"EM Roth","year":"2014","unstructured":"Roth EM, Taskinen MR, Ginsberg HN et al (2014) Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24\u00a0week, double-blind, randomized, phase 3 study. Int J Cardiol 176:55\u201361","journal-title":"Int J Cardiol"},{"key":"1708_CR22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Eng J Med. 372:1489\u20131499","journal-title":"N Eng J Med."},{"key":"1708_CR23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D et al (2015) Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 36:1186\u20131194","journal-title":"Eur Heart J"},{"key":"1708_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP et al (2015) Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 169:906\u2013915","journal-title":"Am Heart J"},{"key":"1708_CR25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB et al (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380:1995\u20132006","journal-title":"Lancet"},{"key":"1708_CR26","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"23","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M et al (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled, phase III clinical trial of evolocumab. J Am Coll Cardiol 23:2531\u20132540","journal-title":"J Am Coll Cardiol"},{"key":"1708_CR27","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P et al (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380:2007\u20132017","journal-title":"Lancet"},{"key":"1708_CR28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ et al (2014) Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia The LAPLACE-2 randomized clinical trial. JAMA 311:1870\u20131882","journal-title":"JAMA"},{"key":"1708_CR29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R et al (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients the GAUSS randomized trial. JAMA 308:2497\u20132506","journal-title":"JAMA"},{"key":"1708_CR30","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"23","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D et al (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance the GAUSS-2 randomized, placebo-controlled phase 3 trial of evolocumab. J Am Coll Cardiol 23:2541\u20132548","journal-title":"J Am Coll Cardiol"},{"key":"1708_CR31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M et al (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Eng J Med 370:1809\u20131819","journal-title":"N Eng J Med"},{"key":"1708_CR32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","volume":"115","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM, Neutel J, Cropp A et al (2015) Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo controlled, dose ranging study in statin-treated subject with hypercholesterolemia. Am J Cardiol 115:1212\u20131221","journal-title":"Am J Cardiol"},{"key":"1708_CR33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C et al (2012) Atorvastatin with or without an antibody to PCSK9 in Primary Hypercholesterolemia. N Eng J Med 367:1891\u20131900","journal-title":"N Eng J Med"},{"key":"1708_CR34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2016.07.111","volume":"252","author":"W Peng","year":"2016","unstructured":"Peng W, Peng W, Qian Z et al (2016) Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: a systematic review and meta-analysis. Atherosclerosis 252:50\u201360","journal-title":"Atherosclerosis"},{"key":"1708_CR35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","volume":"4","author":"N Sattar","year":"2016","unstructured":"Sattar N, Preiss D, Robinson GJ et al (2016) Lipid-lowering efficacy of PCSK9 inhibitor evolocumab (AMG145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 4:403\u2013410","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"1708_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"23","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L et al (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 23(13):123","journal-title":"BMC Med"},{"key":"1708_CR37","doi-asserted-by":"crossref","first-page":"e001937","DOI":"10.1161\/JAHA.115.001937","volume":"4","author":"C Li","year":"2015","unstructured":"Li C, Lin L, Zhang W et al (2015) Efficiency and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 4:e001937","journal-title":"J Am Heart Assoc"},{"issue":"163","key":"1708_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","volume":"2015","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Kolodziejczak M, Shulze V et al (2015) Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and a meta-analysis. Ann Intern Med 2015(163):40\u201351","journal-title":"Ann Intern Med"},{"key":"1708_CR39","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","volume":"35","author":"EA Stein","year":"2014","unstructured":"Stein EA, Giugliano RP, Koren MJ et al (2014) Efficacy and safety of evolocumab (AMG145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 35:2249\u20132259","journal-title":"Eur Heart J"},{"key":"1708_CR40","unstructured":"ClinicalTrial.gov NCT02207634 clinicaltrials.gov\/ct2\/show\/NCT02207634"},{"key":"1708_CR41","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Tardif JC, Amarenco P et al (2017) Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Eng J Med 376:1517\u20131526","journal-title":"N Eng J Med"},{"key":"1708_CR42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/eci.12264","volume":"44","author":"L Moja","year":"2014","unstructured":"Moja L, Pecoraro V, Ciccolallo L, Dall\u2019Olmo L, Virgili G, Garattini S (2014) Flaws, in animal studies exploring statins and impact on meta-analysis. Eur J Clin Invest 44:597\u2013612","journal-title":"Eur J Clin Invest"},{"key":"1708_CR43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-8-32","volume":"8","author":"JO Friedrich","year":"2008","unstructured":"Friedrich JO, Adhikari NK, Beyene J (2008) The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol 8:32","journal-title":"BMC Med Res Methodol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-017-1708-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1708-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1708-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T08:07:58Z","timestamp":1506326878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-017-1708-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1007\/s11739-017-1708-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}